Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection

Therapeutic Drug Monitoring

Volumn 25, Issue 1, 2003, Pages 88-92

  Al Rawithi, Sameer ^a,b   Hussein, Rajaa F ^a   Alzahranit, Ali ^b  

^a Biol and Med Research Department   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Drug monitoring; Fluorescence; Fluvastatin; High performance liquid chromatography (HPLC); Pharmacokinetics

Indexed keywords

DODECYL SULFATE SODIUM; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; TERT BUTYL METHYL ETHER;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PH; PRIORITY JOURNAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LINEAR MODELS;

EID: 0037307315     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200302000-00013     Document Type: Article

References (18)

1. Kathawala FG. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med Res Rev 1991;11:121-46.
2. Davignon J, Montigny M, Dufcur R. HMG-COA reductase inhibitors: a look back and a look ahead. Can J Cardiol 1992;8:843-64.
3. Yuan J, Tsai MY, Hegland J, et al. Effects of fluvastatin (XU 62 320), a new HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 1991;87:145-57.
4. Hussein O, Schlezinger S, Rosenblat M, et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and it's binding to the LDL. Atherosclerosis 1997;128:11-8.
5. John C, LaRosa, Jiang H, et al. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
6. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998;137(suppl): S101-9.
7. Tse FLS, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992;32:630-8.
8. Knopp HR. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
9. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998;46:49-53.
10. Nakashima A, Saxer C. Niina M, et al. Determination of fluvastatin and its five metabolites in human plasma using simple gradient reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 2001;760:17-25.
11. Manning A, Swanson BN, Emaus NA, et al. A semi-automated radioenzymatic assay for pravastatin and lovastatin in human serum. Pharm Res 1989;6(suppl):237.
12. Tsay H, Reiss A, Stouffer B, et al. Specific radioimmunoassay for the measurement of pravastatin in human serum. Clin Chem 1989;35:1189.
13. Whigan DB, Ivashkiv E, Cohen AI. Determination of pravastatin sodium and its isomeric metabolite in human urine by HPLC with UV detection. J Pharm Biomed Anal 1989;7:907-12.
14. Funke T, Ivashkiv E, Arnold ME, et al. A capillary GC negative ion chemical ionization MS method for pravastatin sodium in human serum. Biomed Environ Mass Spectrum 1989;18:904-10.
15. Stubbs RJ, Schwartz M, Bayne WF. An HPLC method for the determination of lovastatin, J Chromatogr 1986;383:438-43.
16. Takano T, Abe S, Hata S, A method to quantify Simvastatin and its acid form in human plasma by a GC-MS selected ion-monitoring method. Biomed Environ Mass Spectrum 1990;19:577-85.
17. Kalafsky G, Smith HT. High performance liquid chromatographic method for the determination of fluvastatin in human plasma. J Chromatogr 1993;614:307-13.
18. Siekmeier R, Lattke P. Mix C, et al. Dose dependency of fluvastatin pharmacokinetics in serum determined by reversed phase HPLC. J Cardiovasc Pharmacol Ther 2001;6:137-45.